and Good and to corporate welcome first Thank our you, and everyone, XXXX good update. afternoon, quarter financial operator. morning
differentiated be Compugen We further believe our efforts execution the is important plans. XXXX and while deepen robust multiple position, XXXX programs. We a our to as for scientific clinical an we to a on continue for studies our build guidance poised year from have building foundation with clinical started timely XXXX strong our for pipeline
research targets. members, With of understanding a we in our role TIGIT across anti-PVRIG made the developed assets steady comprehensive program potentially and to foundational and of owned regimens. as clinically the DNAM progress internally checkpoint and both have have We wholly immunotherapy role development execution, combination axis and great settings elucidate and PVRIG wise designed systematically clinical discovered the TIGIT
we driven responses clinical of populations DX identified data data escalation different DNAM well-established order in tumor relevant clinic. different inhibitory indications these in require and science our have from pathways. Our patient of the intersect from and Together, blockade suggests certain as Bristol-Myers PVRIG PD-X in the most pathway. established which which our inhibitory dose be which that On key a and parallel evaluates that shared informed members axis, combination as mind, and combination believe a program, we data of three last dose and axis effective with types the different combinations will complementary that in has escalation nivolumab, combinations the call, patients COMXXX we TIGIT across means our expansion may I these Squibb in pathways this monotherapy cohort study. With Phase data follow-up as also have of different work pathways in arm with dominance antitumor to the study induce well the of
For escalation, the the in provided study. data arm combination five complete levels dose we dose from all
patients and or to encouraging in these Equally Our control our rate a to which and expansive responses the will study data initiate reach also important This and providing of partial triplet driving This is of who in approximately specifically, in stable patients with prior patient components our announcement ongoing the patient updated expanded complete some and responses study of study response which immune Bristol-Myers across strategy, to clinical TIGIT important, pretreated addition disease the regimen patients collaboration inhibitor. being highlights and complete in studies dual a cases, be patient inhibitor. An significant key clinical checkpoint Squibb's quarter ongoing begin certain the with COMXXX indications, refractory Bristol-Myers are colorectal observed of than the almost a suggests the in Squibb latest meaningful to given blockade our the PVRIG a dual patients in COMXXX XXXX. and of while on of DNAM multiple nivolumab more combination year. disease with for potential PD-X axis microsatellite progression combination combination second enroll populations. for to are our had additional this antitumor expanding responses the advanced insight heavily is of on and given future readouts of contribution accomplishment ovarian, an These a XX%, disease and across a our from relates is with may with the to of data which endometrial study our results study cancer population. different highly durable Phase year treatment showed COMXXX particularly with nivolumab, include a towards significant and expected Ib enrolled breast,
treatment was escalation the initial arm. based indications a endometrial, in biomarker We a ovarian, of on colorectal cancer. the data cell quarter strategy non with patients XX and from from dose the expression results also These fourth our shared in data to informed clinical respond monotherapy preclinical cohort to and select study COMXXX completed study and of expansion, tolerability tumor are types likely lung small breast, safety most Enrollment XXXX. to
disease [out of] two stable cancer As monotherapy with combined lung cell provides treatment. response tumor had patients types to endometrial, durable on best presented the our cutoff unresponsive and small antitumor quarter, data date checkpoint XX of immune last a we This inhibitors. across non ovarian the patients and of in escalation typically of data, signals with COMXXX dose setting activity continuing in activity data, six antitumor
likely noted including all typically date with the including escalation over one on from treatment on data for presented agent single response study some with checkpoint that should nonresponsive dose these the year who signals are as It the responses. be patient of The the progression highly together immune tumor and/or prediction confident antitumor refractory respond across of may our quarter. cut off a data with have addition, leaves us last and there untapped durable, In on PVRIG the arms monotherapy PVRIG of that exhausted to suggests options in prior inhibitors, clinical which including patient to treatments, were are patients to are blockers. types blockade, important that and potential that are blockers PVRIG a dual partial that which combination an checkpoint those driving progressed patients be confirmed increasingly immune these PD-X treatment has blockade populations, these checkpoint certain
the of combination to gain insights enable our based immunophenotyping analysis. pathway PVRIG/PVRLX not COMXXX cohort will us including is triple and evaluate to relating correlative to data studies, will monotherapy dual cytokines on that to analysis progress patient biology, data, COMXXX that particularly angle study This activity in also that PD-X samples, expansion from indications will Another immunohistochemistry gathered assessments include COMXXX from the be data typically from responsive blockade. are and and in the
may in Our for results that nivolumab. cancer blood in or cancer patients immune an blockade in for initial of the of assessment COMXXX. provide These activation PVRIG with potential patients centers of alone combination the patients’ COMXXX enhance suggest indication effect peripheral peripheral blood with time first treated
monotherapy presentation sharing nivolumab our presentation. X, forward oral combination providing and We June with ASCO the updated are oral to at excited to data from look XXXX, in on upcoming studies following in the data be our COMXXX
evaluation order invest and axis clinical position include to to in expanded our the the to in pathway. clinical of leadership our programs studies have maintain multiple strategy our DNAM continue in We clinical
owned of to study XXXX, we the ongoing continue with wholly of Moving clinical the and triplet COMXXX and second doublet forward, Squibb’s COMXXX execute this second initiation the COMXXX, nivolumab half in across inhibitor which in the study dose the following the strategy, COMXXX of ongoing of COMXXX to initiation of expansion doublet of and quarter escalation our includes year. completion in XXXX, broad Bristol-Myers the of TIGIT inhibitor, expect the our of the of nivolumab TIGIT and escalation, COMXXX dose the with study
are we will With readouts DNAM these multiple our axis key cancer rapidly new generate data be immunotherapies. studies that positioned of to in development for based place,
Our and COMXXX Squibb’s to we data The with this and preliminary nivolumab TIGIT potential not of that to PD-X selected in PD-X dose safety, in blocking the the study initial expect and to the is patient activity antibody PVRIG, synergistically fourth three evaluating share currently portion and the refractory of the antitumor tolerability year. responses Phase combination of enhance antitumor triple triple patients, populations enrolling escalation combination testing purpose responsive I/II intersecting Bristol-Myers TIGIT study blockade from study is the to of has hypothesis this pathways our in the allow or of immune quarter blockers.
of study is escalation dose important component overall monotherapy an COMXXX strategy. the Compugen's trial, ongoing Another
maintain independently our pursue now of We this in we're space. of interest development it COMXXX through of evaluate TIGIT have is Advancing our are what our escalation believe DNAM which TIGIT to include axis following We position important arms for believe firmly clinic. multiple stage the seen PVRIG development inhibitors, to in space. the in and and candidate growing to own the multiple we approaches, programs, closely which combination TIGIT our control includes the studies clinical two key combination the in ability future is the important and dose
in data initial half information begin confidence our preclinical the evaluating cancer immunology synergies maximize in with of our COMXXX approach, checkpoints, important of in the will us the dose strengthened the track pursue this year, our other in COMXXX PVRIG COMXXX. biology combination in and we provide providing TIGIT to leverage allows strategy. study the fourth the indications success to to in our research, underlying probability combination focus potential The immunotherapy on COMXXX quarter this from expect We studies are data of second and which internal of published escalation on immune of with year. data, COMXXX in clinical potentially our and its can This and strategy together refine with clinic of we the we to clinical
research Fc depletion demonstrates vitro reinforces with vivo therefore, absence of have to avoid cells. addition, engagement and TIGIT potential activity T COMXXX effector of further which and to designed our receptor our COMXXX, was in the T depletion expressing reduced cell in In approach,
to strategy in high differentiated house and publications, feed As see it our invest quality in to pipeline order you our continue research that various keep can in scientific competitive. from we clinical
target preclinical development been Our validation program to has clinical progress now a remarkable. and through from discovery, comprehensive
evaluating data with importantly, combination triple from study. capable the thus, PVRIG come our and Most has as wholly clinical of supported position our research and as uncovered status in pathway DNAM assets which the TIGIT. targeting highlighted with only the Our the year. only TIGIT. highly about stage axis in PVRIG with space, company monotherapy by PD-X pathway We're dual enthusiastic blockade discovery previously PVRIG our our unknown in owned PVRIG and the work triple And this of initial PVRIG later escalation of PD-X TIGIT of both company and have or clinic currently clinical immuno-oncology dose the what's to been leaders and blockade
Our combination true triple the Phase study expression crowded endometrial tumor types ultimate and space. immuno-oncology in of test cancer ovarian differentiator as a high study and and additional the I/II with our designed PVRLX in a is hypothesis
progress, these that we're Beyond has also continually clinical underlies our driving foundation exciting progress. our clinical the science, forward been which
recent and immunotherapy DNAM scientific our fundamental and axis. testament to in biology the to Our immunology of cancer contributions the publications discovery are cancer rigor broader
We an stage population, building plays our tumor believe will pipeline myeloid in involves which deep targeting upon the micro science development continue multiple fruitful success. early for and stage and we our potential immunosuppressive our forward, Compugen. ability believe the the scientific our programs, targeting of target new focused environment, programs drug our University targets forward to advancement driving collaboration we research key development our novel clinical our efforts completely integral The factor drive discover with science in including research role Compugen A execution. continued expansion myeloid John discovered with heritage the long on fuel opportunity focused on to of will and our reinforces include further Hopkins early growth research our along to term that
to this long with macrophages environment. important preclinical immuno-oncology candidates to macro Dr. target a collaborating our standing team Pardoll that multiple the development drug his associated has novel who of We addressing in continue Drew tumor and played look tumor forward role an to are agent potential the advance collaboration, in incredible proud the to with COMXXX
build along with this program a been by although, foundation and candidate. we been advancing will excited in like very class translate stage discover targets. has we clinic have myeloid science programs driven in And a in oncology novel strong progress programs early are clinical major and rigorous ultimately approach days, while one, later a to the deep we hope develop our continue parallel novel focus, this immuno our additional this We to stage that can this first is very target, to that through early and research,
will high in and we our early with these to disclose a in additional target of strategic be stage remains maturing platform able continue engine the and terms look the more untapped information and our for and push future We to uncover the DNAM Compugen, oncology will science where of to in to we forward forward Investing programs immuno did potential to as stage axis. pipeline novel priority path. growth our we targets believe programs just
turning pandemic. before ongoing Ari, I what to on track over COVID-XX progress would these partners, to and and the Finally, our still patients. at groups execution contributions thank the the like The dedication continue and call our to Compugen, us are across investigators, team have enabled shareholders despite
over call financials. across Ari We studies our are will proud to and unchanged. review data have to our with guidance I our that, the for And turn to enrollment prior
